Objects
Loo, Colleen, Glozier, Nick, Alonzo, Angelo, Dong, Vanessa, Martin, Donel, Nikolin, Stevan, Mitchell, Philip B., Berk, Michael, Carter, Gregory, Hackett, Maree, Leyden, John, Hood, Sean, Barton, David, Somogyi, Andrew A., Lapidus, K, Stratton, E, Gainsford, K, Garg, D, Thornton, NLR, Fourrier, C, Richardson, K, Rozakis, D, Scaria, A, Baune, Bernhard T., Mihalopoulos, C, Chatterton, ML, McDonald, WM, Boyce, P, Holtzheimer, PE, Kozel, FA, Riva-Posse, P, Rodgers, A, Mills, Natalie T., Fitzgerald, Paul, Glue, Paul, Sarma, Shanthi, Galvez-Ortiz, Veronica, Hadzi-Pavlovic, Dusan. Cambridge University Press; 2023. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.
Martin, Donel M., Harvey, Anna J., Hackett, Maree, Mills, Natalie, Sarma, Shanthi, Somogyi, Andrew, Rodgers, Anthony, Loo, Colleen K., Baune, Bernard, Berk, Michael, Carter, Gregory L., Dong, Vanessa, Glozier, Nick, Glue, Paul, Hood, Sean, Hadzi-Pavlovic, Dusan. Elsevier; 2024. Cognitive outcomes from the randomised, active-controlled Ketamine for Adult Depression Study (KADS).